Sara leads, develops, and implements the company's strategy on all patient advocacy initiatives and various state government affairs programs. Patient advocacy is dedicated to helping to improve the well-being of patients, caregivers and families impacted by serious rare diseases. The strategy will focus on external engagement with multiple professional and patient advocacy organizations to continue to build and evolve CRISPR Therapeutics partnerships with these important groups and bringing the patient voice into drug development. In state government affairs, Sara will maintain a strong working relationship with legislators, national and state organizations and be a resource to them on industry issues. Creating coalitions with advocacy groups as well as associations. Working closely with trade associations and other industry leaders to affect legislative outcomes.